Caris Life Sciences,�Inc. CAI
- Market cap
- $9.1B
- P/E
- 85.1×
Follow CAI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 22.86 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 42.50 |
High Price
|
|||
| — | — | — | — | — | — | — | — | 1,769 | 1,846 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 306 | 412 | 812 |
Revenue
|
|||
| — | — | — | — | — | — | — | 29.17% | 43.37% | 66.40% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | (341) | (282) | (68) |
EBT
|
|||
| — | — | — | — | — | — | — | (111.53%) | (68.38%) | (8.38%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | (341) | (282) | (68) |
Net Income
|
|||
| — | — | — | — | — | — | — | 54 | 56 | 35 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 8.76 | 11.61 | 4.86 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (9.77) | (7.94) | (3.22) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | (7.90) | (6.91) | 0.50 |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | (0.64) | (0.24) | (0.10) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | (8.54) | (7.15) | 0.40 |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | (70.40) | 3.45 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 35 | 35 | 167 |
Shares
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 5.56 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 7.81 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 5.04 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | (4.55) | (4.55) | 61.14 |
EV/FCF
|
|||
| — | — | — | — | — | — | — | (276) | (245) | 83 |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | (22) | (8) | (16) |
Capex
|
|||
| — | — | — | — | — | — | — | (298) | (254) | 67 |
FCF
|
|||
| — | — | — | — | — | — | — | — | 50 | 871 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 380 | 379 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | 312 | (421) |
Net Debt
|
|||
| — | — | — | — | — | — | — | 0 | (2,499) | 577 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | (220.09%) | (73.22%) |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 18.05% |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 55.99% |
ROE
|
|||
Caris Life Sciences,�Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IBRX ImmunityBio, Inc. | $9.2B | 0.0× | Compare |
| CYTK Cytokinetics, Incorporated | $9.0B | 0.0× | Compare |
| ARWR Arrowhead Pharmaceuticals, Inc. | $9.3B | 0.0× | Compare |
| PTGX Protagonist Therapeutics, Inc. | $8.9B | 117× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TGTX TG Therapeutics, Inc. | $8.8B | 18.9× | Compare |
| KYMR Kymera Therapeutics, Inc. | $9.7B | 0.0× | Compare |
| PCVX Vaxcyte, Inc. | $8.5B | 0.0× | Compare |
| ABVX Abivax SA Sponsored ADR | $8.2B | 0.0× | Compare |
Caris Life Sciences,�Inc. (CAI) key facts
- Caris Life Sciences,�Inc. (CAI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- As of September 25, 2026, CAI traded at $31.98, a market capitalization of $9.1 billion.
- Return on equity was 56.0% and debt-to-equity 0.66.
Caris Life Sciences,�Inc. (CAI) Latest News
22 Sep
Caris Life Sciences (CAI) moved past a key buy point after a prolonged correction from a peak of 42.50 on Aug. 22 of last year, leaving shares extended. The company relies on artificial intelligence and related tech to profile molecules of interest to the life sciences industry. Past price peak and current extension imply potential short-term trading interest without signaling a fundamental shift in long-term trajectory.
18 Sep
Caris Life Sciences shares rose 10% the prior day with analysis pointing to possible further gains through 2026. Stock price jump and 2026 share outlook signal noticeable effects on valuation and investor views.
6 Sep
Caris Life Sciences reports lung cancer research update suggesting possible 7% undervaluation. Lung cancer research update may shift market views on valuation and performance.
27 Aug
Caris Life Sciences published a study in npj Precision Oncology showing AI-guided therapy selection predicts longer survival in pancreatic cancer patients. Study publication validates AI platform for pancreatic cancer and supports commercial growth in precision oncology.
6 Aug
Caris Life Sciences collaborated with ECOG-ACRIN and NRG Oncology on a study demonstrating a multimodal AI method to predict late distant recurrence risk in HR+ early breast cancer. Study results validate Caris multimodal AI for oncology risk prediction and strengthen its market position.
Caris Life Sciences posted record revenue and volume in Q2 2026. Record revenue and volume signal strong growth that can shift company trajectory and investor views.
Caris Life Sciences, Inc. released Q2 2026 earnings results during its earnings call. Quarterly earnings updates deliver financial metrics that can shift investor views on performance.
5 Aug
Caris Life Sciences reported second quarter 2026 financial results and increased 2026 revenue guidance. Quarterly results with raised revenue guidance signal stronger performance and positive market reaction.
Caris Life Sciences Q2 earnings call highlighted revenue figures, operational updates, and pipeline progress in precision oncology diagnostics. Q2 earnings call delivers financial metrics and outlook that can shift near-term investor sentiment without major strategic overhauls.
17 Jul
Caris Life Sciences launches in-house PTEN test after FDA approval for prostate cancer. FDA approval enables launch of PTEN test expanding Caris prostate cancer diagnostics with major market potential.
Caris Life Sciences (CAI) stock slumped 47% and now appears undervalued based on current valuation metrics. 47% stock slump already altered market valuation and may influence near-term investor positioning without shifting core operations.
14 Jul
Caris Life Sciences adds PTEN IHC testing to expand precision oncology offerings for metastatic prostate cancer. PTEN IHC addition broadens Caris diagnostic capabilities in core prostate cancer market.
10 Jul
Caris Life Sciences launches Caris Detect multi-cancer screening test. New multi-cancer test launch expands core diagnostics offerings and market reach.
1 Jul
Caris Life Sciences launches Caris Detect, the world's most sensitive multi-cancer early detection blood test. Launch of flagship multi-cancer detection test strengthens core diagnostics business and market positioning.
30 Jun
Caris Life Sciences, Inc. advances AI-driven precision medicine expansion to drive stock growth. AI-driven precision medicine expansion represents a major strategic move that could significantly alter Caris Life Sciences' trajectory and investor sentiment.
17 Jun
Caris Life Sciences, Inc. (CAI) announces a $100 million share repurchase program. A $100 million repurchase program signals management confidence in valuation and can provide short-term support to shares without altering long-term operations.
20 May
Billionaire Stanley Druckenmiller has taken a position in lesser-known Caris Life Sciences stock, signaling his confidence in the company's prospects. Druckenmiller's backing may moderately lift investor sentiment and visibility for Caris Life Sciences without fundamentally shifting its core trajectory.
19 May
Caris Life Sciences advances precision oncology initiatives while its shares continue trading below analyst targets. Precision oncology progress supports potential growth in core diagnostics but share price lag signals limited immediate market re-rating.
17 May
Billionaire sells mega-cap stock position to fund AI bet tied to Caris Life Sciences (CAI). Billionaire AI allocation may bring modest capital and visibility to CAI without altering core operations.
15 May
Caris Life Sciences published a study on the Caris Lookback Program, demonstrating the ongoing clinical value of comprehensive testing with Caris MI Cancer Seek. Study publication validates clinical benefits of core comprehensive testing product, potentially boosting market sentiment and competitive positioning in precision oncology.
13 May
Caris Life Sciences plans aggressive expansion into larger oncology market post-IPO, fueled by 79% revenue surge. Post-IPO expansion and 79% revenue growth represent major strategic moves boosting competitive positioning and investor sentiment.
11 May
Caris Life Sciences published a study showing whole exome measurement of tumor mutational burden results in increased overall survival compared to estimates from targeted gene panels. Study validates superiority of Caris's whole exome TMB over targeted panels, boosting competitive positioning in precision oncology.
9 May
Caris Life Sciences (CAI) reports Q1 revenue surge and launches new AI-powered cancer tests, raising questions for investors on whether action is required. Q1 revenue surge and new AI cancer tests represent major growth and innovation in precision oncology, likely altering trajectory and investor sentiment.
8 May
Caris Life Sciences submitted an application to the New York State Department of Health seeking authorization for its Caris Assure blood-based testing. Seeking New York authorization for Caris Assure enables potential expansion of blood-based molecular profiling in a major market, significantly enhancing competitive positioning and revenue prospects.
7 May
Caris Life Sciences (CAI) Q1 2026 earnings call transcript details quarterly financial results, revenue growth, molecular profiling advancements, strategic partnerships, and forward guidance amid expanding precision medicine market. Earnings call reveals key financial metrics, growth strategies, and outlook that significantly shape investor expectations and stock trajectory.
Caris Life Sciences, Inc. (CAI) reported first quarter 2026 financial results. Quarterly financial results announcements typically drive significant shifts in investor sentiment and stock valuation.
Caris Life Sciences released Q1 earnings call highlights detailing financial results, operational updates, and forward-looking guidance. Q1 earnings highlights cover financial performance and strategic outlook with moderate influence on market sentiment and trajectory.
5 May
Caris Life Sciences launches Caris MI Clarity, the first and only AI-powered test to predict both early and late distant recurrence risk in breast cancer at the time of diagnosis. Launch of pioneering AI test for breast cancer recurrence enhances Caris's precision oncology leadership and drives future revenue growth.
4 May
Caris Life Sciences, Inc. (CAI) received MolDX approval for Caris ChromoSeq, a comprehensive genomic profiling assay that sequences the entire tumor genome to detect all major cancer genes and fusion genes, advancing access for patients with myeloid malignancies. MolDX approval enables Medicare reimbursement for Caris ChromoSeq in myeloid malignancies, significantly expanding market access and revenue potential in precision oncology diagnostics.
29 Apr
Caris Life Sciences published a study validating Caris AI Insights for predicting Temozolomide treatment benefits in glioblastoma patients. Validation study bolsters credibility of Caris AI platform in precision oncology, potentially driving adoption, partnerships, and market growth.